8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Published . Updated .
Key takeaways
- 8-K - NEKTAR THERAPEUTICS filed an 8-K with the SEC on Nov 12 (a notice of a material company event).
- Exposed: NKTR
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - NEKTAR THERAPEUTICS filed an 8-K with the SEC on Nov 12 (a notice of a material company event).
Directly affected
- NKTR Nektar Therapeutics-19.6% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Nektar Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+25.0% 30d
Eli Lilly and is a peer of Nektar Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+9.5% 30d
Johnson & Johnson is a peer of Nektar Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+13.5% 30d
AbbVie is a peer of Nektar Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.7% 30d
Merck is a peer of Nektar Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+12.2% 30d
Abbott Laboratories is a peer of Nektar Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NKTR | -0.15% | +1.26% | base | after close | after close | after close | after close |
| XLV | -1.79% | +0.38% | base | after close | after close | after close | after close |
| LLY | -5.27% | +0.16% | base | after close | after close | after close | after close |
| JNJ | -2.55% | -0.98% | base | after close | after close | after close | after close |
| ABBV | -1.00% | -0.21% | base | after close | after close | after close | after close |
| MRK | -0.13% | +0.71% | base | after close | after close | after close | after close |
| ABT | +2.53% | +2.97% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-12 AccNo: 0001213900-26-118964 Size: 287 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Nektar Therapeutics (NKTR) since “8-K - NEKTAR THERAPEUTICS (0000906709) (Filer),” compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | -0.21% | final price |
| ABBV | five days earlier | -1.00% | final price |
| ABT | three days earlier | +2.97% | final price |
| ABT | five days earlier | +2.53% | final price |
| JNJ | three days earlier | -0.98% | final price |
| JNJ | five days earlier | -2.55% | final price |
| LLY | three days earlier | +0.16% | final price |
| LLY | five days earlier | -5.27% | final price |
| MRK | three days earlier | +0.71% | final price |
| MRK | five days earlier | -0.13% | final price |
| Nektar Therapeutics (NKTR) | three days earlier | +1.26% | final price |
| Nektar Therapeutics (NKTR) | five days earlier | -0.15% | final price |
| XLV | three days earlier | +0.38% | final price |
| XLV | five days earlier | -1.79% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 69 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 36 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 43 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 48 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 36 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 59 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 69 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 85 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 36 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 41 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 55 days before publication. Filed 12 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Nektar Therapeutics (NKTR)
Companies carried with this story
- NKTR Nektar Therapeutics
Nektar Therapeutics (NKTR) is linked, with no stored direction, high confidence in the 12 Nov 2026 story “8-K - NEKTAR THERAPEUTICS (0000906709) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> NKTR
How “8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)” reaches Nektar Therapeutics (NKTR)
The 12 Nov 2026 story “8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)” names Nektar Therapeutics (NKTR) because of this story.
What ties Nektar Therapeutics (NKTR) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> NKTR
Price levels for Nektar Therapeutics (NKTR)
NKTR traded between 35.62 and 42.23 across 20 sessions. The latest close on file is 37.78.
A simple score for Nektar Therapeutics (NKTR)
14 out of 100
“8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.